Trial Profile
A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Naratuximab emtansine (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Debiopharm; ImmunoGen
- 07 Jun 2022 Results (n=47) of DL analysis using data from this trials to extract spatial features from digitized slides stained with CD37 and CD20 and their predictive role presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2022 According to a Nucleai media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2022.
- 14 Dec 2021 Results assessing safety and efficacy of naratuximab emtansine plus rituximab to characterize pharmacokinetics and pharmacodynamics in diffuse large B-cell lymphoma and other non-hodgkins B-cell lymphomas, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.